Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy
The international OPTIMA trial found that a genomic test can accurately identify breast cancer patients who do not require chemotherapy. Results suggest that patients over 40 with hormone-sensitive tumors can safely rely on hormone therapy alone.
Why it matters
This could spare thousands of patients annually from the physical and financial burdens of unnecessary chemotherapy treatments.
Results from the international OPTIMA trial indicate that a genomic test can identify many breast cancer patients who can safely avoid chemotherapy without increasing the risk of recurrence .
The report is based on clinical trial data and medical findings, maintaining a strictly objective and scientific focus.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in